Trump Medicaid pricing plan may give Novo Nordisk unexpected financial boost

STAT reports that the White House introduced a plan aimed at lowering the cost of drugs for Medicaid beneficiaries. The policy includes provisions that reduce prices of obesity treatments for seniors, a move that has already benefited companies such as Eli Lilly and Novo Nordisk.

According to the article, Novo Nordisk may receive an additional advantage beyond the existing agreements, potentially increasing its financial position. The report does not provide specific figures but highlights the possibility of an extra “sweetener” for the company.

The piece points out that while the plan is intended to make medicines more affordable, the suggested exception could create a significant win for Novo Nordisk, raising questions about the overall impact of the policy.